NCT03712943 2026-02-09
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
Clinical Trials
26 trialsNCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT03042689 2026-01-08
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
Phase 1 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT03215264 2023-11-09
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03475251 2022-02-18
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02095054 2021-04-01
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03305913 2021-03-26
REMETY
AIO-Studien-gGmbH
Phase 1 Completed
NCT03081494 2020-12-11
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
Phase 1 Completed
NCT02466802 2020-02-20
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Virginia Commonwealth University
Phase 1 Completed
NCT01287598 2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1 Completed
NCT02106845 2019-06-07
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Bayer
Phase 1 Completed
NCT01973868 2019-04-09
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Bayer
Phase 1 Completed
NCT02116894 2019-03-14
REGAL-1
Duke University
Phase 1 Completed
NCT00960258 2017-09-27
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
Bayer
Phase 1 Completed
NCT01853046 2017-02-20
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Bayer
Phase 1 Completed
NCT02398513 2016-08-01
Regorafenib Phase I Study in Mainland Chinese Patients
Bayer
Phase 1 Completed
NCT01117623 2015-11-18
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Bayer
Phase 1 Completed
NCT02001909 2015-08-13
Effect of Neomycin on the Pharmacokinetics of Regorafenib
Bayer
Phase 1 Completed
NCT01322438 2014-12-19
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
Bayer
Phase 1 Completed
NCT01339104 2014-10-01
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Bayer
Phase 1 Completed
NCT00934882 2014-06-02
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
Bayer
Phase 1 Completed
NCT01096030 2013-11-19
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
Bayer
Phase 1 Completed